Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Philip E. Harris, Konstantin Zhernosekov
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours
Beata Kos‐Kudła, Justo P. Castaño, Timm Denecke, et al.
Journal of Neuroendocrinology (2023) Vol. 35, Iss. 12
Open Access | Times Cited: 94
Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives
Eline L. Hooijman, Valery Radchenko, Sui Wai Ling, et al.
EJNMMI Radiopharmacy and Chemistry (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Nicolas Lepareur, Barthélémy Ramée, Marie Mougin‐Degraef, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1733-1733
Open Access | Times Cited: 34
An Overview of Advances in Rare Cancer Diagnosis and Treatment
Grania Christyani, Matthew Carswell, Sisi Qin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1201-1201
Open Access | Times Cited: 11
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies
Nils F. Trautwein, Clemens Hinterleitner, Lena S. Kiefer, et al.
Clinical Nuclear Medicine (2024) Vol. 49, Iss. 3, pp. 207-214
Open Access | Times Cited: 8
Current clinical application of lutetium‑177 in solid tumors (Review)
Tingting Niu, Fan Mi, Binwei Lin, et al.
Experimental and Therapeutic Medicine (2024) Vol. 27, Iss. 5
Open Access | Times Cited: 8
Preclinical Evaluation of [155/161Tb]Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours
Luke Wharton, Scott McNeil, Helen Merkens, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3155-3155
Open Access | Times Cited: 14
Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α
Yana Dekempeneer, Sam Massa, Francis Santens, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 12, pp. 1941-1948
Open Access | Times Cited: 14
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Leandra Piscopo, Emilia Zampella, Sara Pellegrino, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3483-3483
Open Access | Times Cited: 11
Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management
Cody R. Criss, Mina S. Makary
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2076-2091
Open Access | Times Cited: 4
Structure and Function of Somatostatin and Its Receptors in Endocrinology
Bo Zhang, Xue Li, Zhe Wu
Endocrine Reviews (2024) Vol. 46, Iss. 1, pp. 26-42
Open Access | Times Cited: 4
Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres
Gautham Nair, Morgan Black, Kathie Baer, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 86-86
Open Access
Ac-225 radiochemistry through the lens of [225Ac]Ac-DOTA-TATE
Eline L. Hooijman, J. R. de Jong, Carolline M. Ntihabose, et al.
EJNMMI Radiopharmacy and Chemistry (2025) Vol. 10, Iss. 1
Open Access
A study of differences in absorbed dose estimates by images used in dosimetry of Lu-177-DOTATATE therapy
Y Masaki, Yasuo Yamashita, Takuro Isoda, et al.
Radiological Physics and Technology (2025)
Closed Access
Emerging innovations in theranostics for pancreatic neuroendocrine tumors
Anita Karimi, Christina Bogdani, Elisabeth O’Dwyer, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Nicolas Lepareur, Barthélémy Ramée, Marie Mougin‐Degraef, et al.
(2023)
Open Access | Times Cited: 8
Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approaches
Sarvesh Loharkar, Sandip Basu
Expert Review of Precision Medicine and Drug Development (2023) Vol. 8, Iss. 1, pp. 1-32
Open Access | Times Cited: 7
Octreotide modified liposomes that co-deliver paclitaxel and neferine effectively inhibit ovarian cancer metastasis by specifically binding to the SSTR2 receptors
Yang Liu, Jiahua Wang, Jia-qi Si, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 98, pp. 105851-105851
Closed Access | Times Cited: 2
Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2
Tilman Läppchen, Adrianna Bilinska, Eirinaios Pilatis, et al.
Molecules (2024) Vol. 29, Iss. 13, pp. 3093-3093
Open Access | Times Cited: 2
Prostate-Specific Membrane Antigen (PSMA) PET/CT in the Detection and Diagnosis of Hepatocellular Carcinoma (HCC): A Systematic Review and Meta-Analysis
Nicholas Hannah, Catherine Yu, Leya Nedumannil, et al.
Cancers (2024) Vol. 16, Iss. 22, pp. 3865-3865
Open Access | Times Cited: 2
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours
Jelka Kuiper, Eline Zoetelief, Tessa Brabander, et al.
Journal of Neuroendocrinology (2024)
Open Access | Times Cited: 2
Exploring the role of pomalidomide in androgen-dependent prostate cancer: a computational analysis
Shivani Pathak, Vipendra Kumar Singh, Prashant Kumar Gupta, et al.
Molecular Diversity (2024)
Closed Access | Times Cited: 2
Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
Aylin Sibel Cankaya, M. Balzer, Holger Amthauer, et al.
EJNMMI Radiopharmacy and Chemistry (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 5
Interaction of Radiopharmaceuticals with Somatostatin Receptor 2 Revealed by Molecular Dynamics Simulations
Silvia Gervasoni, I. Çetin Öztürk, Camilla Guccione, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 15, pp. 4924-4933
Open Access | Times Cited: 5
Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care
Inna Smalley, Adrienne Boire, Priscilla K. Brastianos, et al.
Pigment Cell & Melanoma Research (2023) Vol. 37, Iss. 1, pp. 51-67
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top